The Analgesic Efficacy of Magnesium and Ketorolac in Ultrasound Supraclavicular Block
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04554862 |
|
Recruitment Status :
Recruiting
First Posted : September 18, 2020
Last Update Posted : September 18, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Despite many regional anesthetic techniques have been described for anesthesia of the brachial plexus which is responsible for the sensory and motor innervation of entire upper limb, still, supraclavicular block (SCB) is the regional anesthetic technique of choice.
SCB has been described as the spinal anesthesia of the upper limb as it offers dense anesthesia of the brachial plexus for the surgical procedures below the arm from elbow to hand. Although the SCB has a high incidence of complications like pneumothorax, the use of ultrasound-guided block improved the safety for the patient. There are several adjuvants have been added to SCB aiming for prolongation of the duration of peripheral nerve block as fentanyl, alpha 2 adrenergic agonist (Dexmedetomidine, Clonidine), tramadol, ketorolac and Magnesium sulfate.
Magnesium has anti-nociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells. Calcium influx leads to a sequence of central sensitization such as windup phenomenon and long term potentiation which are crucial mechanisms that determine the duration and intensity of post-operative pain. Magnesium prevents central sensitization triggered by peripheral nociceptive stimulation in response to painful stimuli.
Non-Steroidal Anti-Inflammatory drugs (NSAID) inhibit synthesis of prostaglandins from arachnoid acid in phospholipid membranes resulting in decreased afferent nociceptive signals from the site of surgery. There are a lot of studies supported the analgesic effect when NSAIDs are concentrated at a peripheral site compared to the systemic administration therapy. Ketorolac is a parenteral NSAIDs. Studies have shown that ketorolac as an adjuvant to local anesthetics during peripheral nerve block enhanced duration and quality of analgesia.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Postoperative Pain | Drug: Magnesium sulfate Drug: Ketorolac Tromethamine Procedure: supraclavicular block | Phase 4 |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 80 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Care Provider) |
| Primary Purpose: | Prevention |
| Official Title: | The Analgesic Efficacy of Adding Magnesium Sulfate Versus Ketorolac to Bupivacaine in Ultrasound-guided Supraclavicular Brachial Plexus Block (A Prospective- Double-blinded Randomized Controlled Trial) |
| Actual Study Start Date : | October 1, 2019 |
| Estimated Primary Completion Date : | November 30, 2020 |
| Estimated Study Completion Date : | November 30, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: the intervention group (M) magnesium sulfate
a 6ml of magnesium sulfate 10% (600mg) will be added to 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
|
Drug: Magnesium sulfate
magnesium sulfate will be added to the block
Other Name: magnesium 10% Procedure: supraclavicular block it is done by ultrasound- guided |
|
Active Comparator: the intervention group (K) ketorolac
a 2ml of ketorolac (30mg) will be added to 4ml of normal saline and 25ml of bupivacaine 0.5% for supraclavicular brachial plexus block
|
Drug: Ketorolac Tromethamine
ketorolac will be added to the block
Other Name: ketorolac Procedure: supraclavicular block it is done by ultrasound- guided |
- the cumulative morphine consumption [ Time Frame: At 24 hours postoperative ]In milligrams
- numerical rating scale (NRS) of postoperative pain [ Time Frame: at 1 hour in the post-anesthesia care unit (PACU) ]the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)
- numerical rating scale (NRS) of postoperative pain [ Time Frame: at 4 hours postoperative ]the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)
- numerical rating scale (NRS) of postoperative pain [ Time Frame: at 8 hours postoperative ]the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)
- numerical rating scale (NRS) of postoperative pain [ Time Frame: at 12 hours postoperative ]the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)
- numerical rating scale (NRS) of postoperative pain [ Time Frame: at 24 hours postoperative ]the severity of postoperative pain estimated by numerical rating scale (NRS) ( where 0 = no pain and 10 = worst imaginable pain)
- incidence of opioid related side-effects [ Time Frame: 5 minutes after supraclavicular block till discharge from PACU ]side effects (nausea, vomiting, pruritus, excessive sedation, and respiratory depression)
- incidence of adverse effects related to the block [ Time Frame: 5 minutes after supraclavicular block till discharge from PACU ]adverse events (e.g. vascular puncture, local anesthetic toxicity, and pneumothorax)
- time to the first requirement of analgesic supplement [ Time Frame: 5 minutes After supraclavicular block till first requirement of analgesic ]In minutes
- Duration of surgical procedures [ Time Frame: 5 minutes after completion of surgical procedures ]In minutes
- Assessment of heart rate [ Time Frame: from the start of the block till completion of surgical procedures ]In beats per minutes
- Assessment of mean blood pressure [ Time Frame: from the start of the block till completion of surgical procedures ]In millimetre mercury (mmHg)
- Assessment of respiratory rate [ Time Frame: from the start of the block till completion of surgical procedures ]Number of breaths per minute
- Assessment of Oxygen saturation [ Time Frame: from the start of the block till completion of surgical procedures ]In percentage through use of pulse oximetry
- Age [ Time Frame: 10 minutes before surgery ]in years
- Weight [ Time Frame: 10 minutes before surgery ]in kilograms (kg)
- Height [ Time Frame: 10 minutes before surgery ]in meters (m)
- Body mass index [ Time Frame: 10 minutes before surgery ]in kg/m square
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) physical status from I to III participants who were scheduled for surgical procedures of the arm from elbow to hand
Exclusion Criteria:
- Patient refusal.
- Contraindication to regional anesthesia (coagulopathy, allergy to the local anesthetic or any adjuvants added, severe thrombocytopenia, pre-existing neuropathy in the operative limb, infection at puncture site).
- Sepsis.
- Pregnant or lactating women.
- Hepatic or renal dysfunction.
- Any drug or opioid abuse.
- Surgical procedures for more than 3h.
- Advanced cardiac diseases.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04554862
| Contact: Eman M Ahmed, Bch | 01008872472 ext 002 | drhouse2007@gmail.com | |
| Contact: Safaa G Ragab, MD | 01004631943 ext 002 | safaagbr705@gmail.com |
| Egypt | |
| Fayoum University hospital | Recruiting |
| Madīnat Al Fayyūm, Faiyum Governorate, Egypt, 63514 | |
| Contact: Safaa G Ragab, MD 01004631943 ext 002 safaagbr705@gmail.com | |
| Contact: Yasser S Mostafa, M.Sc. 01010509735 ext 002 ysm03@fayoum.edu.eg | |
| Principal Investigator: | Safaa G Ragab, MD | Faculty of medicine, Fayoum university |
| Responsible Party: | Safaa Gaber Ragab, Lecturer of anesthesiology, Fayoum University Hospital |
| ClinicalTrials.gov Identifier: | NCT04554862 |
| Other Study ID Numbers: |
M419 |
| First Posted: | September 18, 2020 Key Record Dates |
| Last Update Posted: | September 18, 2020 |
| Last Verified: | September 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Magnesium Ketorolac Supraclavicular block |
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Ketorolac Ketorolac Tromethamine Magnesium Sulfate Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anesthetics Central Nervous System Depressants Anti-Arrhythmia Agents Anticonvulsants Calcium Channel Blockers Membrane Transport Modulators Calcium-Regulating Hormones and Agents Tocolytic Agents Reproductive Control Agents |

